Skip to main content


Media Coverage

Biosimilar Rules Likely To Survive ACA Battle, Lawyers Say

2 March 2017
Intellectual Property partner Lisa Ferri (New York) and Litigation & Dispute Resolution partner Christopher Mikson (Washington DC) are quoted in this article discussing uncertainty surrounding Affordable Care Act provisions for licensing biosimilar products.
The Build a Report feature requires the use of cookies to function properly. Cookies are small text files that are placed on your computer by websites that you visit. They are widely used in order to make websites work, or work more efficiently. If you do not accept cookies, this function will not work. For more information please see our Privacy Policy

You have no pages selected. Please select pages to email then resubmit.